Mylan to buy marketing rights to MS treatment from Israel's Mapi Pharma
(Reuters) - Drugmaker Mylan NV is acquiring global marketing rights to an experimental multiple sclerosis treatment from Israel's Mapi Pharma Ltd, the companies said on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Health | Israel Health | Marketing | Middle East Health | Multiple Sclerosis | Pharmaceuticals